

Table 15.6
Steroid Avoidance Rate at Discharge, 1999 to 2008
Recipients of Heart Transplants

| Discharge Regimen | | Year of Transplant | | | | | | | | | |
|----------------------|------------------|--------------------|-------|-------|-------|-------|-------|-------|-------|-------|--------|
| | | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 |
| Total | Patients | 1,849 | 1,909 | 1,914 | 1,905 | 1,817 | 1,779 | 1,849 | 1,919 | 1,963 | 1,951 |
| | Steroids Avoided | 80 | 102 | 54 | 56 | 134 | 140 | 120 | 151 | 218 | 244 |
| | Rate | 4.3% | 5.3% | 2.8% | 2.9% | 7.4% | 7.9% | 6.5% | 7.9% | 11.1% | 12.5% |
| CyA | Patients | 216 | 89 | 37 | 47 | 34 | 13 | 14 | 27 | 19 | 13 |
| | Steroids Avoided | 10 | 13 | 6 | 1 | 2 | 2 | 2 | 3 | 1 | 1 |
| | Rate | 4.6% | 14.6% | 16.2% | 2.1% | 5.9% | 15.4% | 14.3% | 11.1% | 5.3% | 7.7% |
| Tac | Patients | 43 | 41 | 68 | 75 | 60 | 38 | 44 | 46 | 58 | 66 |
| | Steroids Avoided | 2 | 2 | 5 | 2 | 7 | 3 | 7 | 11 | 13 | 21 |
| | Rate | 4.7% | 4.9% | 7.4% | 2.7% | 11.7% | 7.9% | 15.9% | 23.9% | 22.4% | 31.8% |
| CyA+MMF | Patients | 748 | 1,078 | 1,011 | 825 | 805 | 739 | 615 | 595 | 525 | 407 |
| | Steroids Avoided | 18 | 37 | 18 | 15 | 37 | 34 | 30 | 37 | 47 | 38 |
| | Rate | 2.4% | 3.4% | 1.8% | 1.8% | 4.6% | 4.6% | 4.9% | 6.2% | 9.0% | 9.3% |
| Tac+MMF | Patients | 151 | 161 | 371 | 460 | 540 | 688 | 893 | 1,001 | 1,174 | 1,297 |
| | Steroids Avoided | 1 | 5 | 7 | 16 | 48 | 47 | 48 | 71 | 137 | 165 |
| | Rate | 0.7% | 3.1% | 1.9% | 3.5% | 8.9% | 6.8% | 5.4% | 7.1% | 11.7% | 12.7% |
| CyA+Aza | Patients | 478 | 301 | 204 | 136 | 92 | 83 | 48 | 42 | 29 | 15 |
| | Steroids Avoided | 14 | 21 | 9 | 11 | 10 | 14 | 7 | 3 | 3 | 4 |
| | Rate | 2.9% | 7.0% | 4.4% | 8.1% | 10.9% | 16.9% | 14.6% | 7.1% | 10.3% | 26.7% |
| Tac+Aza | Patients | 36 | 39 | 25 | 25 | 24 | 22 | 20 | 26 | 20 | 27 |
| | Steroids Avoided | 3 | 1 | 1 | 2 | 2 | 4 | 4 | 1 | 4 | 1 |
| | Rate | 8.3% | 2.6% | 4.0% | 8.0% | 8.3% | 18.2% | 20.0% | 3.8% | 20.0% | 3.7% |
| CyA+Siro | Patients | 11 | 12 | 3 | 18 | 38 | 2 | 1 | 2 | - | 2 |
| | Steroids Avoided | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | - | 0 |
| | Rate | 0.0% | 8.3% | 0.0% | 5.6% | 2.6% | 0.0% | 0.0% | 0.0% | - | 0.0% |
| Tac+Siro | Patients | 2 | 17 | 39 | 108 | 32 | 15 | 21 | 19 | 6 | 5 |
| | Steroids Avoided | 0 | 0 | 0 | 3 | 1 | 2 | 6 | 8 | 5 | 5 |
| | Rate | 0.0% | 0.0% | 0.0% | 2.8% | 3.1% | 13.3% | 28.6% | 42.1% | 83.3% | 100.0% |
| Siro+MMF | Patients | - | - | 4 | 7 | 18 | 19 | 16 | 22 | 5 | 4 |
| | Steroids Avoided | - | - | 0 | 0 | 1 | 2 | 1 | 1 | 0 | 0 |
| | Rate | - | - | 0.0% | 0.0% | 5.6% | 10.5% | 6.3% | 4.5% | 0.0% | 0.0% |
| Other Regimen | Patients | 164 | 171 | 152 | 204 | 174 | 160 | 177 | 139 | 127 | 115 |
| | Steroids Avoided | 32 | 22 | 8 | 5 | 25 | 32 | 15 | 16 | 8 | 9 |
| | Rate | 19.5% | 12.9% | 5.3% | 2.5% | 14.4% | 20.0% | 8.5% | 11.5% | 6.3% | 7.8% |

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Includes patients receiving first transplants of any organ with a functioning graft at discharge and any immunosuppressive drug use recorded at discharge.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

Table 15.6 (Continued)
Steroid Withdrawal Rate at One Year Following Transplantation, 1999 to 2007
Recipients of Heart Transplants

| Discharge Regimen | | Year of Transplant | | | | | | | | |
|-------------------|-----------|--------------------|-------|-------|-------|-------|-------|-------|-------|-------|
| | | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 |
| Total | Patients | 1,591 | 1,596 | 1,691 | 1,679 | 1,518 | 1,538 | 1,587 | 1,623 | 1,605 |
| | Steroids | | | | | | | | | |
| | Withdrawn | 303 | 279 | 359 | 391 | 390 | 359 | 441 | 445 | 467 |
| | Rate | 19.0% | 17.5% | 21.2% | 23.3% | 25.7% | 23.3% | 27.8% | 27.4% | 29.1% |
| CyA | Patients | 191 | 67 | 27 | 43 | 25 | 11 | 10 | 23 | 18 |
| | Steroids | | | | | | | | | |
| | Withdrawn | 29 | 7 | 5 | 13 | 4 | 3 | 3 | 2 | 3 |
| | Rate | 15.2% | 10.4% | 18.5% | 30.2% | 16.0% | 27.3% | 30.0% | 8.7% | 16.7% |
| Tac | Patients | 37 | 34 | 59 | 64 | 42 | 32 | 34 | 27 | 39 |
| | Steroids | | | | | | | | | |
| | Withdrawn | 19 | 12 | 14 | 20 | 11 | 10 | 16 | 14 | 9 |
| | Rate | 51.4% | 35.3% | 23.7% | 31.3% | 26.2% | 31.3% | 47.1% | 51.9% | 23.1% |
| CyA+MMF | Patients | 670 | 936 | 926 | 743 | 701 | 667 | 550 | 522 | 442 |
| | Steroids | | | | | | | | | |
| | Withdrawn | 136 | 161 | 177 | 161 | 159 | 158 | 133 | 136 | 113 |
| | Rate | 20.3% | 17.2% | 19.1% | 21.7% | 22.7% | 23.7% | 24.2% | 26.1% | 25.6% |
| Tac+MMF | Patients | 119 | 134 | 320 | 393 | 444 | 597 | 770 | 852 | 957 |
| | Steroids | | | | | | | | | |
| | Withdrawn | 19 | 25 | 80 | 75 | 121 | 143 | 243 | 242 | 312 |
| | Rate | 16.0% | 18.7% | 25.0% | 19.1% | 27.3% | 24.0% | 31.6% | 28.4% | 32.6% |
| CyA+Aza | Patients | 415 | 246 | 171 | 115 | 76 | 65 | 38 | 36 | 25 |
| | Steroids | | | | | | | | | |
| | Withdrawn | 75 | 40 | 40 | 30 | 22 | 12 | 5 | 11 | 3 |
| | Rate | 18.1% | 16.3% | 23.4% | 26.1% | 28.9% | 18.5% | 13.2% | 30.6% | 12.0% |
| Tac+Aza | Patients | 31 | 35 | 21 | 21 | 19 | 17 | 16 | 21 | 12 |
| | Steroids | | | | | | | | | |
| | Withdrawn | 3 | 7 | 2 | 4 | 6 | 2 | 7 | 7 | 5 |
| | Rate | 9.7% | 20.0% | 9.5% | 19.0% | 31.6% | 11.8% | 43.8% | 33.3% | 41.7% |
| CyA+Siro | Patients | 11 | 10 | 3 | 17 | 34 | 2 | 1 | 2 | - |
| | Steroids | | | | | | | | | |
| | Withdrawn | 1 | 2 | 1 | 11 | 17 | 0 | 0 | 0 | - |
| | Rate | 9.1% | 20.0% | 33.3% | 64.7% | 50.0% | 0.0% | 0.0% | 0.0% | - |
| Tac+Siro | Patients | 1 | 2 | 36 | 101 | 30 | 12 | 14 | 11 | 0 |
| | Steroids | | | | | | | | | |
| | Withdrawn | 0 | 0 | 2 | 23 | 11 | 3 | 5 | 8 | - |

(Continued)

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Includes patients receiving first transplants of any organ with steroid use at transplant discharge, and who have a functioning graft and maintenance drug use one year after transplantation.

Transplants prior to year 1999 are not reported due to insufficient reporting of immunosuppressive drug use.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

Table 15.6 (Continued)
Steroid Withdrawal Rate at One Year Following Transplantation, 1999 to 2007
Recipients of Heart Transplants

| Discharge Regimen | | Year of Transplant | | | | | | | | |
|----------------------|----------------|--------------------|-------|-------|-------|-------|-------|-------|-------|-------|
| | | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 |
| Tac+Siro | Rate | 0.0% | 0.0% | 5.6% | 22.8% | 36.7% | 25.0% | 35.7% | 72.7% | - |
| Siro+MMF | Patients | - | - | 3 | 5 | 16 | 14 | 14 | 18 | 3 |
| | Steroids | - | - | 1 | 0 | 3 | 1 | 1 | 3 | 0 |
| | Withdrawn Rate | - | - | 33.3% | 0.0% | 18.8% | 7.1% | 7.1% | 16.7% | 0.0% |
| Other Regimen | Patients | 116 | 132 | 125 | 177 | 131 | 121 | 140 | 111 | 109 |
| | Steroids | 21 | 25 | 37 | 54 | 36 | 27 | 28 | 22 | 22 |
| | Withdrawn Rate | 18.1% | 18.9% | 29.6% | 30.5% | 27.5% | 22.3% | 20.0% | 19.8% | 20.2% |

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Includes patients receiving first transplants of any organ with steroid use at transplant discharge, and who have a functioning graft and maintenance drug use one year after transplantation.

Transplants prior to year 1999 are not reported due to insufficient reporting of immunosuppressive drug use.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

Table 15.6 (Continued)
Steroid Withdrawal Rate at Two Years Following Transplantation, 1998 to 2006
Recipients of Heart Transplants

| Discharge Regimen | | Year of Transplant | | | | | | | |
|-------------------|-----------|--------------------|-------|-------|-------|-------|-------|-------|-------|
| | | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 |
| Total | Patients | 1,482 | 1,558 | 1,581 | 1,561 | 1,458 | 1,432 | 1,362 | 1,332 |
| | Steroids | | | | | | | | |
| | Withdrawn | 422 | 471 | 558 | 546 | 556 | 579 | 584 | 604 |
| | Rate | 28.5% | 30.2% | 35.3% | 35.0% | 38.1% | 40.4% | 42.9% | 45.3% |
| CyA | Patients | 176 | 66 | 28 | 39 | 22 | 10 | 9 | 20 |
| | Steroids | | | | | | | | |
| | Withdrawn | 48 | 21 | 9 | 21 | 9 | 5 | 3 | 3 |
| | Rate | 27.3% | 31.8% | 32.1% | 53.8% | 40.9% | 50.0% | 33.3% | 15.0% |
| Tac | Patients | 37 | 31 | 56 | 58 | 39 | 30 | 28 | 22 |
| | Steroids | | | | | | | | |
| | Withdrawn | 21 | 17 | 21 | 26 | 11 | 21 | 15 | 16 |
| | Rate | 56.8% | 54.8% | 37.5% | 44.8% | 28.2% | 70.0% | 53.6% | 72.7% |
| CyA+MMF | Patients | 640 | 903 | 863 | 699 | 676 | 615 | 475 | 435 |
| | Steroids | | | | | | | | |
| | Withdrawn | 156 | 245 | 268 | 237 | 243 | 240 | 187 | 177 |
| | Rate | 24.4% | 27.1% | 31.1% | 33.9% | 35.9% | 39.0% | 39.4% | 40.7% |
| Tac+MMF | Patients | 95 | 130 | 300 | 364 | 425 | 560 | 643 | 687 |
| | Steroids | | | | | | | | |
| | Withdrawn | 27 | 39 | 139 | 127 | 172 | 231 | 317 | 332 |
| | Rate | 28.4% | 30.0% | 46.3% | 34.9% | 40.5% | 41.3% | 49.3% | 48.3% |
| CyA+Aza | Patients | 388 | 244 | 162 | 101 | 73 | 61 | 33 | 30 |
| | Steroids | | | | | | | | |
| | Withdrawn | 127 | 95 | 59 | 28 | 28 | 16 | 8 | 17 |
| | Rate | 32.7% | 38.9% | 36.4% | 27.7% | 38.4% | 26.2% | 24.2% | 56.7% |
| Tac+Aza | Patients | 29 | 32 | 21 | 20 | 19 | 16 | 14 | 18 |
| | Steroids | | | | | | | | |
| | Withdrawn | 7 | 7 | 5 | 3 | 6 | 5 | 8 | 6 |
| | Rate | 24.1% | 21.9% | 23.8% | 15.0% | 31.6% | 31.3% | 57.1% | 33.3% |
| CyA+Siro | Patients | 10 | 10 | 3 | 17 | 33 | 2 | 1 | 1 |
| | Steroids | | | | | | | | |
| | Withdrawn | 5 | 6 | 1 | 13 | 24 | 1 | 0 | 0 |
| | Rate | 50.0% | 60.0% | 33.3% | 76.5% | 72.7% | 50.0% | 0.0% | 0.0% |
| Tac+Siro | Patients | 0 | 15 | 30 | 97 | 30 | 12 | 14 | 11 |
| | Steroids | | | | | | | | |
| | Withdrawn | - | 0 | 3 | 34 | 12 | 10 | 7 | 8 |

(Continued)

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Includes patients receiving first transplants of any organ with steroid use at transplant discharge, and who have a functioning graft and maintenance drug use two years after transplantation.

Transplants prior to year 1998 are not reported due to insufficient reporting of immunosuppressive drug use.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

Table 15.6 (Continued)
Steroid Withdrawal Rate at Two Years Following Transplantation, 1998 to 2006
Recipients of Heart Transplants

| Discharge Regimen | | Year of Transplant | | | | | | | |
|----------------------|----------------|--------------------|-------|-------|-------|-------|-------|-------|-------|
| | | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 |
| Tac+Siro | Rate | - | 0.0% | 10.0% | 35.1% | 40.0% | 83.3% | 50.0% | 72.7% |
| Siro+MMF | Patients | - | - | 3 | 5 | 16 | 14 | 13 | 15 |
| | Steroids | - | - | 1 | 0 | 4 | 1 | 3 | 6 |
| | Withdrawn Rate | - | - | 33.3% | 0.0% | 25.0% | 7.1% | 23.1% | 40.0% |
| Other Regimen | Patients | 107 | 127 | 115 | 161 | 125 | 112 | 132 | 93 |
| | Steroids | 31 | 41 | 52 | 57 | 47 | 49 | 36 | 39 |
| | Withdrawn Rate | 29.0% | 32.3% | 45.2% | 35.4% | 37.6% | 43.8% | 27.3% | 41.9% |

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Includes patients receiving first transplants of any organ with steroid use at transplant discharge, and who have a functioning graft and maintenance drug use two years after transplantation.

Transplants prior to year 1998 are not reported due to insufficient reporting of immunosuppressive drug use.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.